Gu G, Roland B, Tomaselli K, Dolman CS, Lowe C, Heilig JS
It was first approved as Egrifta in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, and it remains a prescription drug with a regulator-reviewed label, including a defined dose, defined contraindications, and required safety monitoring
GIP, or glucose-dependent insulinotropic polypeptide, is another gut hormone that: Stimulates insulin release Supports fat metabolism May contribute to enhanced weight loss when paired with GLP-1 By acting on both pathways, tirzepatide delivers a synergistic effect that may produce greater results than GLP-1 alone
Moreover, pharmacologic treatments cannot reset the circadian clock rhythm